Immunotherapy

Findings from a recent retrospective study demonstrated a multiyear decline in the population-level mortality of melanoma. This decline has been associated with the FDA approval of 10 novel treatments for metastatic melanoma since 2011.

In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, discussed the most exciting developments in renal cell carcinoma in the past year.

In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, discussed the use of combination therapies for treatment of renal cell carcinoma.

Carey K. Anders, MD, medical director for the Center for Brain and Spine Metastasis at Duke Cancer Institute, discussed treatment options for brain metastasis across breast cancer, including HER2-positive, triple-negative or hormone receptor-positive disease.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about novel combination therapies currently under investigation for the treatment of small cell lung cancer.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about how to determine optimal treatment strategies for patients with small cell lung cancer.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about promising immunotherapeutic approaches currently being studied in small cell lung cancer.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about common small cell lung cancer treatment-related toxicities.